Label: VASOSTRICT- vasopressin injection

  • NDC Code(s): 42023-164-01, 42023-164-10, 42023-164-25, 42023-190-01, view more
    42023-219-01, 42023-219-10, 42023-220-01, 42023-220-10
  • Packager: Par Pharmaceutical, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated March 26, 2021

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use VASOSTRICT® safely and effectively. See full prescribing information for VASOSTRICT®.

    Vasostrict® (vasopressin injection) for intravenous use
    Initial U.S. Approval: 2014

    INDICATIONS AND USAGE

    • Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. (1)

    DOSAGE AND ADMINISTRATION

    • Dilute 20 units/mL single dose vial or 200 units/10 mL (20 units/mL) multiple dose vial contents with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. (2.1)
    • The 40 units/100 mL and 60 units/100 mL single dose vials do not require further dilution prior to administration. (2.1)
    • Post-cardiotomy shock: 0.03 to 0.1 units/minute (2.2)
    • Septic shock: 0.01 to 0.07 units/minute (2.2)

    DOSAGE FORMS AND STRENGTHS

    • Injection: 20 units/mL in a single dose vial and 200 units/10 mL (20 units/mL) in a multiple dose vial.   To be used after dilution. (3)
                      40 units/100 mL (0.4 units/mL) and 60 units/100 mL (0.6 units/mL) in single dose vials.  Ready to use. (3)

    CONTRAINDICATIONS

    • Vasostrict® 10 mL multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol.  The 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. (4)

    WARNINGS AND PRECAUTIONS

    • Can worsen cardiac function. (5.1)
    • Reverisible diabetes insipidus (5.2)

    ADVERSE REACTIONS

    The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    • Pressor effects of catecholamines and Vasostrict® are expected to be additive. (7.1)
    • Indomethacin may prolong effects of Vasostrict®. (7.2)
    • Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response. (7.3, 7.5)
    • Co-administration of drugs causing diabetes insipidus may decrease the pressor response. (7.6)

    USE IN SPECIFIC POPULATIONS

    • Pregnancy: May induce uterine contractions. (8.1)
    • Pediatric Use: Safety and effectiveness have not been established. (8.4)
    • Geriatric Use: No safety issues have been identified in older patients. (8.5)

    Revised: 3/2021

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Preparation of Solution

    Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit.

    Vasostrict® Solution for Dilution, 20 units/mL and 200 units/10 mL (20 units/mL)

    Dilute Vasostrict® in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.

    Table 1 Preparation of diluted solutions
    Fluid restriction?Final concentrationMix
    Vasostrict®Diluent
     

    No

     

    0.1 units/mL

     

    2.5 mL (50 units)

     

    500 mL

     

    Yes

     

    1 unit/mL

     

    5 mL (100 units)

     

    100 mL

    Vasostrict® Premixed Solution, 40 units/100 mL (0.4 units/mL) and 60 units/100 mL (0.6 units/mL)

    This product does not require further dilution prior to administration.

    2.2 Administration

    In general, titrate to the lowest dose compatible with a clinically acceptable response.

    The recommended starting dose is:

    Post-cardiotomy shock: 0.03 units/minute

    Septic Shock: 0.01 units/minute

    Titrate up by 0.005 units/minute at 10- to 15-minute intervals until the target blood pressure is reached. There are limited data for doses above 0.1 units/minute for post-cardiotomy shock and 0.07 units/minute for septic shock. Adverse reactions are expected to increase with higher doses.

    After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure.

  • 3 DOSAGE FORMS AND STRENGTHS

    Vasostrict® (vasopressin injection, USP) is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single dose vial and 200 units/10 mL (20 units/mL) in a multiple dose vial. To be used after dilution.

    Vasostrict® is also available premixed as 40 units/100 mL (0.4 units/mL) and 60 units/100 mL (0.6 units/mL) in single dose vials. Ready to use.

  • 4 CONTRAINDICATIONS

    Vasostrict® 10 mL multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol.  The 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Worsening Cardiac Function

    A decrease in cardiac index may be observed with the use of vasopressin.

    5.2 Reversible Diabetes Insipidus

    Patients may experience reversible diabetes inspidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin.  Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation.  Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.

  • 6 ADVERSE REACTIONS

    The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

    Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding

    Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia

    Gastrointestinal disorders: Mesenteric ischemia

    Hepatobiliary: Increased bilirubin levels

    Renal/urinary disorders: Acute renal insufficiency

    Vascular disorders: Distal limb ischemia

    Metabolic: Hyponatremia

    Skin: Ischemic lesions

    Postmarketing Experience

    Reversible diabetes insipidus [see Warnings and Precautions (5.2)]

  • 7 DRUG INTERACTIONS

    7.1 Catecholamines

    Use with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters.  Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

    7.2 Indomethacin

    Use with indomethacin may prolong the effect of Vasostrict® on cardiac index and systemic vascular resistance.  Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology (12.3)].

    7.3 Ganglionic Blocking Agents

    Use with ganglionic blocking agents may increase the effect of Vasostrict® on mean arterial blood pressure.  Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology (12.3)].

    7.4 Drugs Suspected of Causing SIADH

    Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict®.  Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

    7.5 Drugs Suspected of Causing Diabetes Insipidus

    Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasostrict®. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no available data on Vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted.

    Clinical Considerations

    Dose adjustments during pregnancy and the postpartum period: Because of increased clearance of vasopressin in the second and third trimester, the dose of Vasostrict® may need to be increased [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].

    Maternal adverse reactions: Vasostrict® may produce tonic uterine contractions that could threaten the continuation of pregnancy.

    8.2 Lactation

    There are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.

    8.4 Pediatric Use

    Safety and effectiveness of Vasostrict® in pediatric patients with vasodilatory shock have not been established.

    8.5 Geriatric Use

    Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Warnings and Precautions (5), Adverse Reactions (6), and Clinical Pharmacology (12.3)].

  • 10 OVERDOSAGE

    Overdosage with Vasostrict® can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.

    Direct effects will resolve within minutes of withdrawal of treatment.

  • 11 DESCRIPTION

    Vasopressin is a polypeptide hormone. Vasostrict® is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration.

    The 1 mL solution contains vasopressin 20 units/mL, 1.36 mg sodium acetate buffer and Water for Injection, USP.  The 10 mL solution contains vasopressin 20 units/mL, 1.36 mg sodium acetate buffer, chlorobutanol, NF 0.5% as a preservative and Water for Injection, USP.  Sodium hydroxide and hydrochloric acid are included to adjust to a pH of 3.8.

    The 100 mL solution contains vasopressin 0.4 units/mL or 0.6 units/mL. Each mL of the 0.4 unit/mL strength also contains dextrose anhydrous, 0.0546 mg acetic acid, 0.012 mg sodium acetate and Water for Injection, USP. Each mL of the 0.6 unit/mL strength also contains dextrose anhydrous, 0.0546 mg acetic acid, 0.012 mg sodium acetate and Water for Injection, USP. Sodium hydroxide and hydrochloric acid are included to adjust to a pH of 3.8.

    The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-Phenylalanyl-L-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide. It is a white to off-white amorphous powder, freely soluble in water. The structural formula is:

    Chemical Structure

    Molecular Formula: C46H65N15O12S2                 Molecular Weight: 1084.23

    One mg is equivalent to 530 units.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Vasopressin causes vasoconstriction by binding to V1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V2 receptors which are coupled to adenyl cyclase.

    12.2 Pharmacodynamics

    At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V1-receptors and release of prolactin and ACTH via V3 receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V2 receptors. In addition, vasopressin has been demonstrated to cause vasodilation in numerous vascular beds that are mediated by V2, V3, oxytocin and purinergic P2 receptors. 

    In patients with vasodilatory shock vasopressin in therapeutic doses increases systemic vascular resistance and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and cardiac output. The pressor effect is proportional to the infusion rate of exogenous vasopressin. The pressor effect reaches its peak within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients.

    12.3 Pharmacokinetics

    Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min. Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion. 

    Distribution Vasopressin does not appear to bind plasma protein. The volume of distribution is 140 mL/kg.

    Elimination

    At infusion rates used in vasodilatory shock (0.01 to 0.1 units/minute), the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory shock. The apparent t1/2 of vasopressin at these levels is ≤10 minutes.

    Metabolism

    Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity.

    Excretion

    Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine.

    Specific Populations

    Pregnancy: Because of a spillover into blood of placental vasopressinase, the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy, the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery, the clearance of vasopressin returns to preconception baseline within two
    weeks.

    Drug Interactions Indomethacin more than doubles the time to offset for vasopressin’s effect on peripheral vascular resistance and cardiac output in healthy subjects [see Drug Interactions (7.2)].

    The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects [see Drug Interactions (7.3)].

    Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the in vitro bacterial mutagenicity (Ames) test and the in vitro Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa.

    13.2 Animal Toxicology and/or Pharmacology

    No toxicology studies were conducted with vasopressin.

  • 14 CLINICAL STUDIES

    Increases in systolic and mean blood pressure following administration of vasopressin were observed in 7 studies in septic shock and 8 in post-cardiotomy vasodilatory shock.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Vasostrict® (vasopressin injection, USP) is a clear, practically colorless solution for intravenous administration available as:

    NDC 42023-164-10: A carton of 10 single dose vials. Each vial contains vasopressin 1 mL at 20 units/mL.

    NDC 42023-164-25: A carton of 25 single dose vials. Each vial contains vasopressin 1 mL at 20 units/mL.

    NDC 42023-190-01: A carton of 1 multiple dose vial. Each vial contains vasopressin 10 mL at 200 units/10 mL (20 units/mL).

    NDC 42023-219-10: A carton of 10 single dose vials. Each vial contains vasopressin 100 mL at 40 units/100 mL (0.4 units/mL).

    NDC 42023-220-10: A carton of 10 single dose vials. Each vial contains vasopressin 100 mL at 60 units/100 mL (0.6 units/mL).

    Store between 2°C and 8°C (36°F and 46°F). Do not freeze.

    Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], USP Controlled Room Temperature), anytime within the labeled shelf life. Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 month expiration date. If the manufacturer’s original expiration date is shorter than the revised expiration date, then the shorter date must be used. Do not use Vasostrict® beyond the manufacturer’s expiration date stamped on the vial.

    After initial entry into the 10 mL vial, the remaining contents must be refrigerated. Discard the refrigerated 10 mL vial after 30 days after first puncture.

    The storage conditions and expiration periods are summarized in the following table.

     

    Unopened Refrigerated

    2°C to 8°C (36°F to 46°F)

    Unopened Room Temperature

    20°C to 25°C (68°F to 77°F)

    Do not store above 25°C (77°F)

      Opened (After First Puncture)

    1 mL Vial

    Until manufacturer expiration date

    12 months or until manufacturer expiration date, whichever is earlier

    N/A

     10 mL Vial

    Until manufacturer expiration date

    12 months or until manufacturer expiration date, whichever is earlier

    30 days

     100 mL VialUntil manufacturer expiration date12 months or until manufacturer expiration date, whichever is earlierN/A

  • SPL UNCLASSIFIED SECTION

    Distributed by:
    Par Pharmaceutical
    Chestnut Ridge, NY 10977

    R03/2021
    OS164J-01-90-XX

    Vasostrict® is a registered trademark of Par Pharmaceutical Companies, Inc.

  • PRINCIPAL DISPLAY PANEL – 20 units/mL x 25 Vial Carton

    NDC 42023-164-25
    Rx Only

    Vasostrict®
    (Vasopressin Injection, USP)

    20 Units per mL

    For Intravenous Infusion
    Must be diluted prior to use
    Store between 2°C and 8°C (36°F and 46°F).

    Do not store above 25°C (77°F).

    Vials may be held at 20°C to 25°C (68°F to 77°F) for up to 12 months.

    1 mL x 25 Single Dose Vials

    Vasostrict 1 mL Carton
  • PRINCIPAL DISPLAY PANEL - 20 units/mL x 10 Vial Carton

    NDC 42023-164-10
    Rx Only

    Vasostrict®
    (Vasopressin Injection, USP)

    20 Units per mL

    For Intravenous Infusion
    Must be diluted prior to use 

     Store between 2°C and 8°C (36°F and 46°F). Do not store above 25°C (77°F).
    Vials may be held at 20°C to 25°C (68°F to 77°F) for up to 12 months.

    1 mL x 10 Single Dose Vials

    Vasostrict 1 mL Carton - 10 pack

  • PRINCIPAL DISPLAY PANEL – 200 units/10 mL x 1 Vial Carton

    NDC 42023-190-01
    Rx Only

    Vasostrict®
    (Vasopressin Injection, USP)

    200 Units per 10 mL
    (20 Units per mL) 

    For Intravenous Infusion
    Must be diluted prior to use
    Store between 2°C and 8°C (36°F and 46°F).

    Do not store above 25°C (77°F).

    Vials may be held at 20°C to 25°C (68°F to 77°F) for up to 12 months.

    10 mL x 1 Multiple Dose Vial

    Vasostrict 10 mL Carton
  • PRINCIPAL DISPLAY PANEL - 40 units/100 mL x 10 Vial Carton

    NDC 42023-219-10
    Rx Only

    Vasostrict®
    (Vasopressin Injection, USP)

    40 Units per 100 mL
    (0.4 units per mL)

    For Intravenous Infusion

    Ready to Use 
    100 mL x 10 Single Dose Vials

    Vasostrict 40 unit/100 mL Carton
  • PRINCIPAL DISPLAY PANEL - 60 units/100 mL x 10 Vial Carton

    NDC 42023-220-10
    Rx Only

    Vasostrict®
    (Vasopressin Injection, USP)

    60 Units per 100 mL
    (0.6 units per mL)

    For Intravenous Infusion

    Ready to Use 
    100 mL x 10 Single Dose Vials

    Vasostrict 60 units/100 mL Carton

  • INGREDIENTS AND APPEARANCE
    VASOSTRICT 
    vasopressin injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42023-164
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VASOPRESSIN, UNSPECIFIED (UNII: Y87Y826H08) (VASOPRESSIN, UNSPECIFIED - UNII:Y87Y826H08) VASOPRESSIN, UNSPECIFIED20 [USP'U]  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SODIUM ACETATE (UNII: 4550K0SC9B) 1.36 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42023-164-2525 in 1 CARTON11/12/2014
    1NDC:42023-164-011 mL in 1 VIAL; Type 0: Not a Combination Product
    2NDC:42023-164-1010 in 1 CARTON08/17/2020
    2NDC:42023-164-011 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20448511/12/2014
    VASOSTRICT 
    vasopressin injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42023-190
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VASOPRESSIN, UNSPECIFIED (UNII: Y87Y826H08) (VASOPRESSIN, UNSPECIFIED - UNII:Y87Y826H08) VASOPRESSIN, UNSPECIFIED20 [USP'U]  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SODIUM ACETATE (UNII: 4550K0SC9B) 1.36 mg  in 1 mL
    CHLOROBUTANOL (UNII: HM4YQM8WRC) 5 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42023-190-011 in 1 CARTON02/27/2017
    110 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20448502/27/2017
    VASOSTRICT 
    vasopressin injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42023-219
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VASOPRESSIN, UNSPECIFIED (UNII: Y87Y826H08) (VASOPRESSIN, UNSPECIFIED - UNII:Y87Y826H08) VASOPRESSIN, UNSPECIFIED0.4 [USP'U]  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    DEXTROSE (UNII: IY9XDZ35W2)  
    ACETIC ACID (UNII: Q40Q9N063P) 0.0546 mg  in 1 mL
    SODIUM ACETATE (UNII: 4550K0SC9B) 0.012 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42023-219-1010 in 1 CARTON10/15/2020
    1NDC:42023-219-01100 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20448510/15/2020
    VASOSTRICT 
    vasopressin injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42023-220
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VASOPRESSIN, UNSPECIFIED (UNII: Y87Y826H08) (VASOPRESSIN, UNSPECIFIED - UNII:Y87Y826H08) VASOPRESSIN, UNSPECIFIED0.6 [USP'U]  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    DEXTROSE (UNII: IY9XDZ35W2)  
    ACETIC ACID (UNII: Q40Q9N063P) 0.0546 mg  in 1 mL
    SODIUM ACETATE (UNII: 4550K0SC9B) 0.012 mg  in 1 mL
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42023-220-1010 in 1 CARTON10/15/2020
    1NDC:42023-220-01100 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20448510/15/2020
    Labeler - Par Pharmaceutical, Inc. (092733690)